qualityresearch.com

Are you struggling with the frequent urgency, discomfort, and disruption caused by irritable bowel syndrome with diarrhea (IBS-D)? The unpredictable nature of this condition can make finding reliable relief a daunting task. However, there is hope on the horizon. Innovative new medicines developed through medical research are being investigated as potential solutions. Quality Research in San Antonio is currently conducting a clinical trial for a promising new medication for IBS-D, and you may be eligible to participate. By joining this study, you have the opportunity to find relief for your symptoms and contribute to improving the lives of countless individuals affected by this life-altering condition. Additionally, you could receive up to $525 in compensation for your time and travel expenses. Read on to discover more about the new Enviva IBS-D study and how you can get involved.

What is IBS-Diarrhea?

qualityresearch.comIBS-D, or irritable bowel syndrome with diarrhea, is a common disorder that affects the large intestine. It’s characterized by chronic abdominal pain, bloating, and frequent diarrhea. These symptoms can significantly disrupt daily life, making it difficult to manage work, social activities, and even personal care.

What Causes Irritable Bowel Syndrome (IBS)?

IBS is a complex condition with no single known trigger, but various factors are believed to play a role in its emergence:

  • Gut-Brain Interaction: The gut and brain often miscommunicate, which can disrupt regular bowel function and sensitivity.
  • Gastrointestinal Motility:  Irregular muscle movements in the intestines can cause cramps, pain, and alterations in bowel patterns.
  • Visceral Hypersensitivity: The digestive tract may also become overly sensitive, leading to heightened discomfort and pain even during normal digestion.
  • Psychological Factors: Stress, anxiety, and depression are connected to IBS, potentially worsening symptoms through the gut-brain connection.

What is the Enviva IBS-D Study?

qualityresearch.comThe Quality Research Enviva study is a Phase 2 clinical research study designed to evaluate the effects of an investigational drug on the symptoms of IBS-D. The study lasts approximately 19 weeks and is divided into four key periods:

  • Screening Period: Initial assessments to determine eligibility.
  • Baseline Period: Observation of symptoms without treatment.
  • Dosing Period: Administration of the investigational drug to study its effects.
  • Follow-up Period: Monitoring health and symptoms after treatment ends.

The primary goal of the Enviva study is to see how the investigational drug may help ease unpleasant symptoms like abdominal pain, bloating, and stool consistency. To find out more details or to see if you qualify, visit this page.

Who Can Enroll in the Enviva IBS-D Study?

You may be eligible to participate in the Enviva IBS-D Study if you answer “yes” to the following questions:

  • Are you an adult male or female 18 years of age or older?
  • Have you been diagnosed with IBS-D?
  • Do you expect no changes to your lifestyle, exercise routine, and/or diet during the study?
  • Are you willing to complete a daily eDiary?

If you meet these criteria, you could be a candidate for this important research study. It would help advance our understanding of IBS-D and potentially find new treatments to help you and countless individuals living with this horrible disease.

Why Join Quality Clinical Research?

qualityresearch.comQuality Clinical Research, conveniently located in the Alamo district of San Antonio, is at the forefront of conducting clinical trials to discover breakthrough treatments for IBS-D. Here are just a few of the benefits you receive by joining this study:

  1. No-Cost Health Exam and Medical Evaluation: Rest assured your health is monitored closely by experienced professionals.
  2. Advanced Investigational Medicine: Access to cutting-edge treatments that are not yet available to the public.
  3. Compensation for Your Time and Travel: Receive financial support to cover your time, travel, and expenses during the study.
  4. Contribute to Finding a Cure: Play a vital role in the search for effective treatments for IBS-D, benefiting yourself and millions of others.
  5. No Insurance Necessary: You don’t need to worry about insurance coverage to participate.
  6. No Proof of Residency Required: Your eligibility is not dependent on your residency status.

How to Get Involved

If you’re interested in contributing to this important research and exploring new treatment options for IBS-D, consider joining the Enviva IBS-D study. Visit this page and fill out the form at the bottom or you can also call them at (470) 227-8130 and speak to a patient recruiter who will answer all your questions and help you with the sign-up process.

Quality Research Offering Hope for Millions Suffering from IBS-D

qualityreseach.comLiving with IBS-D can be a daily challenge, and finding effective solutions often feels like a difficult task. Clinical trials offer a valuable opportunity to be a part of essential research aiming to enhance treatments and provide relief to those suffering from IBS-D. Quality Research clinical team is dedicated to bringing tomorrow’s medical advancements to San Antonio today. With over 300 trials conducted and more than 4,000 local participants served, their expertise and compassion have made them a trusted partner for leading pharmaceutical companies. Every study they undertake follows strict FDA guidelines and ensures HIPAA compliance, safeguarding your privacy and security at every step. By participating in a clinical trial at Quality Research, you could play a pivotal role in advancing IBS-D treatments. Your involvement might be instrumental in unlocking new solutions that transform the management of this condition. Clinical studies are vital for developing new treatments that could significantly improve the lives of those living with IBS-Diarrhea. Don’t miss the chance to be a part of this groundbreaking initiative. Join Quality Research IBS-D clinical trial’s mission to revolutionize IBS-D care and make a meaningful impact on the future of treatment options.